[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354161-105":59,"doc-detail-354161-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-drivers-of-prostate-cancer-metastasis-volume-25-emerging-targets-for-precision-therapy","Molecular Drivers of Prostate Cancer Metastasis - Volume 25 - Emerging Targets for Precision Therapy","","Prostate cancer metastasis drives major male cancer mortality by requiring signaling-mediated molecular interactions that enable detachment from the primary tumor and formation of secondary lesions in distant organs. Key pathways highlighted include PI3K/AKT, Wnt/β-catenin, and epithelial-mesenchymal transition (EMT). Dysregulated signaling reduces responsiveness to androgen deprivation therapy and chemotherapy in castration-resistant and metastatic settings. The review evaluates strategies that inhibit AKT and Wnt signals, reverse EMT, and integrate immunotherapy with personalized medicine and liquid biopsy for real-time monitoring of disease evolution.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-drivers-of-prostate-cancer-metastasis-volume-25-emerging-targets-for-precision-therapy/354161/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-drivers-of-prostate-cancer-metastasis-volume-25-emerging-targets-for-precision-therapy/354161.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which molecular pathways are emphasized in driving prostate cancer metastasis?","Question",{"text":112,"@type":113},"The document emphasizes PI3K/AKT signaling, Wnt/β-catenin signaling, and epithelial-mesenchymal transition (EMT) mechanisms, with additional mention of TGF-β signaling in the broader metastatic process.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are current therapies insufficient for metastatic and castration-resistant prostate cancer?",{"text":117,"@type":113},"Androgen deprivation therapy and chemotherapy can help to some extent, but the review states they are insufficient for effective treatment of both castration-resistant prostate cancer (CRPC) and metastatic disease due to reduced responsiveness.",{"name":119,"@type":110,"acceptedAnswer":120},"What emerging treatment directions are proposed for precision therapy?",{"text":121,"@type":113},"It proposes blocking AKT signaling combined with Wnt inhibition and reversing EMT, alongside integrating immunotherapy with personalized medicine and liquid biopsy technologies to improve treatment effects and enable real-time tracking.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354161,1790182619,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","Molecular Drivers of Prostate Cancer Metastasis: Emerging Targets for Precision Therapy  \nTechnology in Cancer Research & Treatment  \nVolume 25: 1-14 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15330338251408321](DOI: 10.1177/15330338251408321)[ ](DOI: 10.1177/15330338251408321)[journals.sagepub.com/home/tct](journals.sagepub.com/home/tct)  \nEmeka Eze Joshua Iweala, PhD 1,2  and Chukwuemeka Pius Nwokoro, MSc 1,2   \nAbstract  \nProstate cancer (PCa) stands as one of the primary cancer diseases affecting male health and represents the principal reason behind death when metastasis develops during late-stage disease. The spread of prostate cancer from its initial site demands intricate molecular interactions through signaling pathways which permit cancer cells to break their attachment to the original tumor mass and form secondary tumor sites in distant organs. Prostate cancer metastasis depends heavily on three main molecular pathways which include the PI3K/AKT signaling cascade along with Wnt/β-catenin pathway and epithelial-mesenchymal transition (EMT) signaling mechanisms. The deregulation of these signaling pathways creates strong contributions toward prostate cancer spread during metastasis and reduction of response to standard treatment methods. Presently available androgen deprivation therapy and chemotherapy have proven successful to some extent yet insufficient for effective treatment of both castrationresistant prostate cancer (CRPC) and metastatic disease. The development of therapies which block AKT signaling combined with Wnt signaling inhibition and reversal of EMT processes creates new treatment opportunities for better cancer outcome results. The combined use of immunotherapy with personalized medicine along with liquid biopsy technologies will improve therapeutic effects by enabling real-time tracking of disease evolution and treatment response. This analysis investigates the molecular processes that drive prostate cancer metastasis and the present therapeutic solutions and the upcoming therapies that try to block these pathways. Numerous treatment approaches and precision medicine strategies combining the integrated treatment approaches may lead to improved therapeutic benefit with fewer adverse effects while delivering more personalized and effective care. This review will majorly focus on the molecular pathways and preclinical treatment options that support metastatic prostate cancer, but briefly outline the clinical progress that is currently shaping the precision therapeutic models.  \nKeywords  \nprostate cancer metastasis, PI3K/AKT signaling pathway, Wnt/β-catenin pathway, epithelial-mesenchymal transition (EMT), precision oncology  \nReceived: 23 June 2025; revised: 17 November 2025; accepted: 12 December 2025  \nIntroduction  \nWorldwide men suffer from prostate cancer which ranks as the primary malignancy affecting them and metastatic prostate cancer leads to the most cancer-related male deaths. Older male adults represent the main group who develops this disease since most prostate cancer diagnoses occur after age 65 . The management of prostate cancer faces considerable difficulties from metastasis because metastatic tumors typically demonstrate decreased responsiveness to established therapy methods. The biological process of prostate cancer metastasis manifests through cancer cell detachment from their origin along with invasion beyond tissue borders until reaching ultimate metastases in bones and lungs and liver.1 According to the latest  \nnational estimates based on the Global Burden of Disease Study, the trends of incidence and mortality of prostate cancer  \n1 Department of Biochemistry, College of Science and Technology, Covenant University, Ota, Nigeria  \n2Covenant Applied Informatics and Communication Africa Centre of Excellence (CApIC-ACE), Covenant University, Ota, Nigeria  \nCorr","cbCaim6oSP3df2jn","https://ap.wps.com/l/cbCaim6oSP3df2jn","pdf",1675423,14,"English","# Abstract\n## Introduction\n## Molecular pathways and therapeutic rationale\n## Precision therapy strategies","[{\"question\":\"Which molecular pathways are emphasized in driving prostate cancer metastasis?\",\"answer\":\"The document emphasizes PI3K/AKT signaling, Wnt/β-catenin signaling, and epithelial-mesenchymal transition (EMT) mechanisms, with additional mention of TGF-β signaling in the broader metastatic process.\"},{\"question\":\"Why are current therapies insufficient for metastatic and castration-resistant prostate cancer?\",\"answer\":\"Androgen deprivation therapy and chemotherapy can help to some extent, but the review states they are insufficient for effective treatment of both castration-resistant prostate cancer (CRPC) and metastatic disease due to reduced responsiveness.\"},{\"question\":\"What emerging treatment directions are proposed for precision therapy?\",\"answer\":\"It proposes blocking AKT signaling combined with Wnt inhibition and reversing EMT, alongside integrating immunotherapy with personalized medicine and liquid biopsy technologies to improve treatment effects and enable real-time tracking.\"}]","Molecular Drivers of Prostate Cancer Metastasis - Volume 25 - Emerging Targets for Precision Therapy | PDF",1790109295,35]